Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The Locations section now lists additional Japanese sites: Aichi-ken, Fukuoka, Hyōgo, Ishikawa-ken, Osaka, and Shizuoka. Location-specific entries were removed and the revision updated to v3.3.3.
    Difference
    0.6%
    Check dated 2025-12-23T07:32:08.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page now shows revision v3.3.2 replacing v3.3.1; no study details or results are affected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T16:31:45.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The Publications section now includes clarifying statements that publications are voluntary input and are auto-filled from PubMed, and the page revision is labeled v3.3.1. The older language about PubMed-generated lists and study results wording has been removed, and 'To avoid being alerted by small changes, set an alert condition by clicking below.'
    Difference
    0.1%
    Check dated 2025-11-24T12:43:24.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Removed the government funding status notice, eliminating the lapse-in-funding banner from the study page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-17T06:25:04.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The update appears to be limited to minor UI/layout adjustments and an updated last update date; the core content (title, conditions, trial arms, eligibility criteria, and outcomes) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T01:00:08.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Major change: version bump to v3.2.0 and an important operating-status notice about government funding and NIH Clinical Center, directing users to official sources.
    Difference
    2%
    Check dated 2025-10-05T09:25:20.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.